This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

NICE guidance - rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

NICE have suggested that (1):

  • rituximab, in combination with glucocorticoids, is recommended as an option for inducing remission in adults with anti-neutrophil cytoplasmic antibody [ANCA]-associated vasculitis (severely active granulomatosis with polyangiitis [Wegener's] and microscopic polyangiitis), only if:
    • further cyclophosphamide treatment would exceed the maximum cumulative cyclophosphamide dose or

    • cyclophosphamide is contraindicated or not tolerated or

    • the person has not completed their family and treatment with cyclophosphamide may materially affect their fertility or

    • the disease has remained active or progressed despite a course of cyclophosphamide lasting 3-6 months or

    • the person has had uroepithelial malignancy.

Notes (1):

  • rituximab is a genetically engineered chimeric (mouse/human) monoclonal antibody that depletes B cells by targeting cells bearing the CD20 surface marker

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.